This is not the most recent version of the article. View current version (25 OCT 2013)

Intervention Protocol

You have free access to this content

Artemisinin-based combination therapy for the treatment of uncomplicated Plasmodium vivax malaria and the prevention of relapses

  1. Nithya Gogtay2,
  2. Felicity Brand3,
  3. Piero Olliaro4,
  4. David Sinclair1,*

Editorial Group: Cochrane Infectious Diseases Group

Published Online: 14 APR 2010

DOI: 10.1002/14651858.CD008492


How to Cite

Gogtay N, Brand F, Olliaro P, Sinclair D. Artemisinin-based combination therapy for the treatment of uncomplicated Plasmodium vivax malaria and the prevention of relapses (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 4. Art. No.: CD008492. DOI: 10.1002/14651858.CD008492.

Author Information

  1. 1

    Liverpool School of Tropical Medicine, International Health Group, Liverpool, UK

  2. 2

    Seth GS Medical College and KEM Hospital, Mumbai, India

  3. 3

    Fordington, Dorchester, UK

  4. 4

    World Health Organization, UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, Switzerland

*David Sinclair, International Health Group, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK. davesinkers@yahoo.com.

Publication History

  1. Publication Status: New
  2. Published Online: 14 APR 2010

SEARCH

This is not the most recent version of the article. View current version (25 OCT 2013)

References

Additional references

Anstey 2009
Baird 1997
  • Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi, et al. Diagnosis of resistance to chloroquine by Plasmodium vivax: Timing of recurrence and whole blood chloroquine levels. American Journal of Tropical Medicine and Hygiene 1997;56(6):621-26.
Baird 2007
  • Baird J K, Schwartz E, Hoffman SL. Prevention and treatment of vivax malaria. Current Infectious Disease Reports 2007;9(1):39-46.
Baird 2009
Barcus 2007
  • Barcus JM, Basri H, Picarima H, Manyakori C, Sekartuti, Elyazar I, et al. Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. American Journal of Tropical Medicine and Hygiene 2007;77:984-91.
Bloland 2003
  • Bloland PB. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria [WHO/HTM/RBM/2003.50]. Geneva: World Health Organization, 2003.
Collins 1996
Dondorp 2009
Galappaththy 2007
  • Galappaththy GNL, Omari AAA, Tharyan P. Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database of Systematic Reviews 2007, Issue Issue 1. Art. No.: CD004389. DOI: 10.1002/14651858.CD004389.pub2.
Genton 2008
  • Genton B, D’Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, et al. Plasmodium vivax and mixed infections are associated with severe malaria in children: A prospective cohort study from Papua New Guinea. PLoS Medicine 2008;5:e127.
Hasugian 2007
  • Hasugian AR, Purba HLE, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, et al. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clinical Infectious Diseases 2007;44:1067-74.
Imwong 2007
  • Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy A, et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. The Journal of Infectious Diseases 2007;195:927-33.
Karunajeewa 2008
  • Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai S, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. New England Journal of Medicine 2008;359:2545-57.
Kochar 2009
  • Kochar DK, Das A, Kochar SK, Saxena V, Sirohi P, Garg S, et al. Severe Plasmodium vivax malaria: A report on serial cases from Bikaner in northwestern India. American Journal of Tropical Medicine and Hygiene 2009;80:194-98.
Mayxay 2004
Mendis 2001
  • Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax infection. American Journal of Tropical Medicine and Hygiene 2001;64(1 suppl):97-106.
Nacher 2004
  • Nacher M, Silachamroon U, Singhasivanon P, Wilairatana P, Phumratanaprapin W, Fontanet A, et al. Comparison of artesunate and chloroquine activities against Plasmodium vivax. Antimicrobial Agents and Chemotherapy 2004;48(7):2751-52.
Nosten 2007
  • Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. American Journal of Tropical Medicine and Hygiene 2007;77 (6 Suppl):181-92.
Price 1996
Price 1999
  • Price R, van Vugt M, Phaipun L, Luxemburger C, Simpson J, McGready R, et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. American Journal of Tropical Medicine and Hygiene 1999;60(4):547-55.
Price 2007
  • Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected but not benign. American Journal of Tropical Medicine and Hygiene 2007;77 (Suppl 6):79-87.
Price 2009
  • Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Current Opinion in Infectious Diseases 2009;22:430-35.
Pukrittayakamee 2000
  • Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, Looareesuwan S, et al. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrobial Agents and Chemotherapy 2000;44(6):1680-5.
Ratcliff 2007a
  • Ratcliff A, Siswantoro H, Kenangalem E, Wuwung M, Brockman A, Edstein MD, et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Transactions of the Royal Society of Tropical Medicine and Hygiene 2007;101:351-9.
Ratcliff 2007b
  • Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open label randomised comparison. Lancet 2007;369:757-65.
Review Manager 5
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
Sinclair 2009
Sumawinata 2003
  • Sumawinata IW, Bernadeta, Leksana B, Sutamihardja A, Purnomo, Subianto B, et al. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. American Journal of Tropical Medicine and Hygiene 2003;68:416-20.
Sutanto 2009
  • Sutanto I, Suprijanto S, Nurhayati, Manoempil P, Baird KJ. Resistance to chloroquine by Plasmodium vivax at Alor in the Lesser Sundas Archipelago in eastern Indonesia. American Journal of Tropical Medicine and Hygiene 2009;81(2):338-42.
Targett 2001
  • Targett G, Drakeley C, Jawara M, von Seidlein L, Coleman R, Deen J, et al. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. Journal of Infectious Diseases 2001;183(8):1254-9.
Taylor 2004
Tjitra 2008
  • Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Medicine 2008;5:e128.
White 1996
White 1999
White 2002
WHO 2006
  • World Health Organization. Roll Back Malaria Dept. Guidelines for the treatment of malaria [WHO/HTM/MAL/2006.1108]. Geneva: World Health Organization, 2006.
WHO 2007
  • World Health Organization. Malaria [Fact sheet no. 94]. www.who.int/mediacentre/factsheets/fs094/en/index.html May 2007 (accessed 1 July 2008).
WHO 2008
  • WHO Global Malaria Programme. World Malaria Report: 2008. Geneva: World Health Organization, 2008.